Home / Investors / Overview

Company Information

CymaBay Therapeutics (Nasdaq: CBAY)

We are a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need. We are evaluating seladelpar in primary biliary cholangitis (PBC). We also have a product program in earlier development that features a unique mechanism of action with potential in chronic diseases.

Stock Information

Last Change Volume

Shares Outstanding: 10,064,495
(as of March 3, 2014)

Company Information

CymaBay Therapeutics
7575 Gateway Blvd
Suite 110
Newark, CA 94560

Investor Relations

LifeSci Advisors, LLC
Hans Vitzthum
(617) 430-7578

Recent News


CymaBay Reports First Quarter 2023 Financial Results and Provides Corporate Update


CymaBay Therapeutics to Report First Quarter of 2023 Financial Results on Monday, May 15, 2023


CymaBay Names Harish Shantharam Chief Financial Officer

Upcoming Event

Jun 1 2023 8:00 am PT

2023 Annual Meeting of Stockholders

June 1, 2023 at 8:00 am PT

Q1 2023 Quarterly Results